肿瘤细胞治疗研究
DISEASE HUB
FOR TREATMENT
现在就能报名的（招募中）排在最前，共 0 项。同一状态内中国中心优先。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性，以登记原文和主治医生判断为准。
FOR RESEARCH
T-Cell Engagers Targeting BCMA, GPRC5D, or FcRH5 in Relapsed/Refractory Multiple Myeloma: The Landscape Beyond CAR-T Cell Therapy-A Systematic Review
Beyond Remission: Risk-Adapted Maintenance and Mechanism-Guided Salvage After CAR T-Cell Therapy for Multiple Myeloma.
对于持续性 MRD 阴性、无髓外疾病且免疫功能正在恢复的许多患者，结构化观察是合适的。持续性或升高的 MRD、残留病灶、侵袭性疾病生物学特征或不利的 CAR-T 细胞动力学，应促使尽早转介临床试验，而非自动进行慢性治疗。挽救治疗可能涉及 BCMA 再靶向、转换为 GPRC5D 或 FcRH5、常规减瘤、放疗、抗体-药物偶联物、双特异性抗体或第二种细胞平台。未来试验应评估无进展生存期，同时评估无感染生存期、无治疗间期、免疫恢复、生活质量以
Bispecific antibodies in the treatment of multiple myeloma.
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins.
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Bispecific antibodies in multiple myeloma: maximizing potential through rational combination therapies.
Case report: Dual-targeted BCMA and CS1 CAR-T-cell immunotherapy in recurrent and refractory extramedullary multiple myeloma.
在接受多轮化疗和放疗的复发难治性多发性骨髓瘤患者中，针对 BCMA 和 CS1 的双靶点 CAR-T 细胞疗法未能有效控制髓外复发。多发性骨髓瘤中 MYBL2 表达升高与较差的预后相关。
Current Novel Targeted Therapeutic Strategies in Multiple Myeloma.
MEMBER ACCOUNT
登录成功会直接打开下一页。
